Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT
Gut microbiota trajectory in pediatric patients undergoing hematopoietic SCT
复制标题
DOI：
10.1038/bmt.2015.16
复制
发表时间：
2015-07-01
影响因子：
4.8
通讯作者：
Candela, M.
中科院分区：
文献类型：
--
作者：
Biagi, E.;Zama, D.;Candela, M.
急性GvHD（aGvHD）是造血SCT（HSCT）治疗血液系统疾病期间的主要并发症。我们对接受 HSCT 的儿科患者进行了第一项纵向研究，从系统发育和功能的角度跟踪肠道微生物群轨迹。从 HSCT 之前开始，一直到移植后 3-4 个月，对发生和未发生 aGvHD 的儿童的肠道微生物群轨迹和短链脂肪酸生产情况进行跟踪。根据我们的研究结果，HSCT 程序暂时导致肠道微生物生态系统的结构和功能破坏，描述了接下来 100 天内的恢复轨迹。 aGvHD 的发生与移植后肠道微生物群重建过程中的特定肠道微生物群特征相关，最有趣的是，在 HSCT 之前。事实上，在 HSCT 前的样本中，非 aGvHD 患者表现出更高丰度的产丙酸拟杆菌，这是一种高度适应性的微生物组共生体，在 HSCT 引起的生态系统破坏期间持续存在。我们的数据表明，肠道微生物生态系统的结构和时间动态可能是 HSCT 成功的相关因素，并为操纵 HSCT 前肠道微生物群配置以有利于肠道中具有免疫调节特性的互惠持久者开辟了前景。
Acute GvHD (aGvHD) is the main complication of hematopoietic SCT (HSCT) during the treatment of hematological disorders. We carried out the first longitudinal study to follow the gut microbiota trajectory, from both the phylogenetic and functional points of view, in pediatric patients undergoing HSCT. Gut microbiota trajectories and short-chain fatty acid production profiles were followed starting from before HSCT and through the 3-4 months after transplant in children developing and not developing aGvHD. According to our findings, HSCT procedures temporarily cause a structural and functional disruption of the gut microbial ecosystem, describing a trajectory of recovery during the following 100 days. The onset of aGvHD is associated with specific gut microbiota signatures both along the course of gut microbiota reconstruction immediately after transplant and, most interestingly, prior to HSCT. Indeed, in pre-HSCT samples, non-aGvHD patients showed higher abundances of propionate-producing Bacteroidetes, highly adaptable microbiome mutualists that showed to persist during the HSCT-induced ecosystem disruption. Our data indicate that structure and temporal dynamics of the gut microbial ecosystem can be a relevant factor for the success of HSCT and opens the perspective to the manipulation of the pre-HSCT gut microbiota configuration to favor mutualistic persisters with immunomodulatory properties in the gut.